Price
No data yet.
Social Signal Score
Revenue
$48.14M+40.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wenbin Jiang
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 682
- Beta
- 1.17
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 3.46
Financials
Revenue
$48.14M+40.0%Net Income
$-12.16M-956.2%EBITDA
$-8.38M-409.7%Free Cash Flow
$-849.0KEPS (diluted)
$-0.09-742.9%Shares Outstanding (diluted)
129.46M+13.9%Operating Expenses
$39.74MCash & Debt
$262.00MReturn of Capital
$0.00Revenue by Segment (annual)
$201.49MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $201.49M | $-66.54M | $-0.52 |
| 2024 | $200.45M | $-6.02M | $-0.05 |
| 2023 | $193.01M | $-12.15M | $-0.09 |
| 2022 | $164.04M | $2.58M | $0.02 |
| 2021 | $127.95M | $3.00M | $0.03 |
| 2020 | $92.84M | $19.41M | $0.02 |
| 2019 | $57.88M | $-16.83M | $-0.13 |
Valuation
CTKBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
…y to Challenge Remaining Finding FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek's favor on three of the four asserted patent claims, finding noninfringement and …
View source ↗
Earnings
Wed, Nov 4(in 2 months)
Consensus estimate $-0.07 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.05 vs $-0.09beat
- Thu, May 7$-0.12 vs $-0.08miss
- Thu, Feb 26$-0.34 vs $-0.02miss
- Wed, Nov 5$-0.01 vs $-0.03beat
- Wed, Aug 6$-0.04 vs $-0.02miss
- Thu, May 8$-0.09 vs $-0.04miss
Estimates and results for CTKB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CTKB officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.